Overview of Vermox-plus

Quick Facts

Property	Description
Active ingredients	Mebendazole, Quinfamide
Form	Tablet, Chewable tablet
Pharmacological class	Antiparasitic Agent (Anthelmintic and Antiprotozoal)
Origin	Synthetic
Target area	Gastrointestinal tract

Vermox-plus is a synthetic, fixed-dose combination antiparasitic medication intended for oral administration. This product is uniquely designed to provide comprehensive coverage against common gastrointestinal infestations by incorporating two distinct active pharmaceutical ingredients.

What Type of Medicine is Vermox-plus?

Vermox-plus is classified as an Antiparasitic Agent, specifically representing a combination of an Anthelmintic and an Antiprotozoal Agent. Mebendazole, one of the primary components, is recognized for its efficacy as an anthelmintic. Clinical data confirms the synergistic benefit of combining these two classes of agents for treating mixed parasitic infections, which is the primary distinguishing feature of the Vermox-plus formulation compared to single-agent treatments. This dual classification enables it to treat infections caused by both parasitic worms (helminths) and single-celled organisms (protozoa, particularly Entamoeba histolytica).

Core Composition and Pharmaceutical Form

The core composition of Vermox-plus is the combination of the active ingredients Mebendazole and Quinfamide. Mebendazole is a benzimidazole derivative widely recognized for its activity against intestinal worms such as hookworm, roundworm, and whipworm. Quinfamide, a dichloroacetyl quinolol derivative, provides the necessary antiamebic action and is indicated for the treatment of intestinal amoebiasis. This medicine is prepared for oral administration, typically provided in the pharmaceutical form of a tablet or chewable tablet, often with considerations for palatability for use in the pediatric patient group.

General Purpose of the Dual-Action Approach

The general purpose of this formulation is to deliver a broad-spectrum therapeutic benefit. The drug is intended for use where there is a confirmed diagnosis or a high suspicion of mixed parasitic infections within the intestinal tract. This strategy is essential because parasitic worm and protozoal infections often co-exist, and the combined activity ensures a more complete and efficient elimination of the causative pathogens. For instance, Vermox-plus is specifically positioned as a solution for comprehensive treatment when both Enterobius vermicularis (pinworm) and intestinal amoeba are suspected.

Regulatory References

World Health Organization

What side effects are possible with Vermox-plus?

Possible side effects and safety information

The safety profile of Vermox-plus (Mebendazole and Quinfamide) is defined by the adverse reactions documented for its active ingredients in official regulatory documents. Adverse reactions are classified by frequency and the body systems affected, in line with government health authority standards.

Frequency and System-Organ Classifications

The most commonly reported adverse effects are categorized as Common and involve Gastrointestinal Disorders. These include experiences such as abdominal pain, diarrhea, nausea, and vomiting. These effects are often transient and may be more pronounced at the start of treatment.

Less frequently reported (Uncommon or Rare) events may affect other systems. Nervous System Disorders can include headache and dizziness. Rare effects may involve Skin and Subcutaneous Tissue Disorders (e.g., rash, urticaria, reversible alopecia) and disturbances in the Blood and Lymphatic System.

Serious Adverse Reactions and Safety Constraints

Official labeling documents a risk of rare but serious adverse reactions, which include severe Hypersensitivity Reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Rare effects on the blood, such as neutropenia and agranulocytosis, have been documented, particularly when associated with higher doses or prolonged duration of therapy. Hepatitis and elevated liver function tests are also noted as rare possibilities.

Specific safety considerations exist for certain populations. Convulsions have been reported in infants below one year of age. Caution is required in patients with Hepatic Impairment due to potential altered concentrations of the medicine. Furthermore, an increased risk of severe skin reactions (SJS/TEN) has been noted when Mebendazole is used concurrently with Metronidazole, a safety constraint explicitly documented in official prescribing information.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents state that suspected overdose with Vermox-plus requires immediate medical intervention. The documented clinical presentation of an acute overdose typically involves severe gastrointestinal manifestations, which include the rapid onset of abdominal cramps, nausea, vomiting, and diarrhea.

When to Seek Immediate Medical Help

Seek immediate medical attention for suspected overdose or the manifestation of any severe systemic effects. Emergency medical care is required for symptoms indicative of rare but serious complications, which are associated with substantially higher than recommended dosages or prolonged exposure. These documented severe outcomes include effects on the Hematologic System (e.g., agranulocytosis and neutropenia) and the Hepatobiliary System (e.g., reversible liver function disturbances and hepatitis).

Management and Monitoring

The official prescribing information confirms that no specific antidote is known for the active ingredients, and treatment is strictly symptomatic and supportive. Regulatory guidance advises that hospital monitoring may be required. Management measures may involve gastric decontamination (e.g., activated charcoal, if appropriate) and fluid replacement. Specific laboratory monitoring of blood counts and liver function is officially recommended following significant exposure to assess for systemic toxicity potential.

Therapeutic Uses of Vermox-plus

What Vermox-plus Treats: Main Uses and Benefits

The medicine is relevant for use in managing a range of parasitic infections and associated symptoms. Based on the properties of its main component, it is commonly used to help with infections caused by intestinal worms, and its combination formula is considered relevant for protozoa.

Targeted Management of Mixed Intestinal Infections

Vermox-plus is commonly used across conditions presenting with episodic or fluctuating manifestations of mixed parasitic infections. It is applied in addressing both intestinal worms (helminths), such as roundworm, pinworm, and hookworm, and symptoms associated with protozoal infections. This approach supports the management of symptoms by addressing both groups of causative agents at once.

Supports Easing Gastrointestinal and Systemic Symptoms

This medication helps address groups of distressing symptoms that may interfere with daily functioning. It is relevant in clinical settings marked by acute diarrhea, severe abdominal cramping, and pain, and is applied in addressing associated systemic imbalance, such as discomfort related to malabsorption and generalized malaise. It contributes to easing the overall symptom load during periods of heightened discomfort.

Managing Symptom Recurrence and Contagion Potential

It is also applied in contexts where additional symptomatic support is needed, particularly to resolve the intensely irritating anal itching and sleep disturbance associated with pinworm infection. The treatment may assist with managing symptoms that create noticeable physiological strain within a family context, as addressing the infection is commonly used in efforts to manage recurrent or episodic manifestations.

“The treatment supports patients during episodes of heightened discomfort by addressing the core symptomatic manifestations.”

Quick Fact: Supports managing Gastrointestinal Symptoms
Helps manage symptom clusters that may become intense or disruptive, such as diarrhea and cramping.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility profile for Vermox-plus is strictly defined by official regulatory documents, establishing who can and who must not use the medication based on age, physiological state, and existing medical conditions.

Populations Allowed and Restricted

Use is officially established for adults and pediatric patients 2 years of age and older. Use is not recommended in children aged 1 to 2 years, as safety and effectiveness are not extensively established in this age group.

Absolute Contraindications

Vermox-plus is contraindicated in several key populations. It must not be used by patients who have a known hypersensitivity to Mebendazole, Quinfamide, or any other component in the formulation. The medicine is also contraindicated in children below the age of 1 year due to insufficient safety data. Official labeling also classifies use during pregnancy as contraindicated.

Conditional Use Requirements

Use requires caution in patients with pre-existing conditions, including hepatic impairment (liver disease), due to the potential for increased systemic drug exposure. Caution is also advised during lactation (breastfeeding), as small amounts of the active ingredient may be present in human milk.

What should I know about interactions with other medicines?

The documented interaction profile for Vermox-plus, based on regulatory labeling for its active components, focuses on specific drug restrictions and pharmacokinetic changes. All interaction information is derived strictly from official government sources.

Documented Restrictions and Exposure Modifiers

Co-administration of the Mebendazole component with Metronidazole is officially recommended to be avoided due to a documented potential increased risk of serious cutaneous adverse reactions, such as Stevens-Johnson syndrome/toxic epidermal necrolysis.

Other medicinal products are documented to alter the drug’s exposure. Cimetidine is noted in regulatory documents as inhibiting Mebendazole's metabolism, which results in an increase in its plasma concentrations. Conversely, the use of Carbamazepine or other Hydantoins may reduce the plasma levels of Mebendazole due to documented enzyme induction, potentially reducing its systemic exposure.

Interaction Type	Interacting Substance	Official Regulatory Outcome
Co-Administration Restriction	Metronidazole	Recommended to be avoided (risk of SJS/TEN)
Increased Exposure	Cimetidine	Inhibits metabolism; increases plasma concentration
Decreased Exposure	Carbamazepine, Hydantoins	Reduces plasma levels (metabolism induction)
Food Interaction	High-fat meal	Increases systemic absorption (AUC/Cmax)

Population-Specific Interaction Notes

The official profile notes that patients with impaired hepatic function may experience a reduction in the metabolism and elimination of Mebendazole. This pharmacokinetic change is officially documented as potentially leading to higher plasma concentrations and increased systemic exposure for this population. Furthermore, administering the product with a high-fat meal is a documented pharmacokinetic interaction that increases the systemic absorption of Mebendazole.

Mechanism of Action

How Vermox-plus Works

Vermox-plus utilizes a dual-mechanism approach targeting distinct biological systems within parasites.

1. Targeting Parasite Structure and Energy Metabolism (Mebendazole)

The Mebendazole component selectively binds to beta-tubulin within parasitic worms (helminths). This interaction interferes with the assembly of essential microtubules, leading to the collapse of the parasite's internal structure and subsequent inhibition of glucose uptake. The resulting energy depletion initiates a rapid series of cellular failures, culminating in irreversible cellular dysfunction and loss of viability.

2. Generating Toxic Intermediates for DNA Damage (Tinidazole)

The Tinidazole component acts as a prodrug that undergoes activation within susceptible anaerobic protozoa and bacteria. Enzymes in these organisms reduce the drug, generating highly reactive cytotoxic intermediates. These compounds inflict extensive damage on the microbial cell's DNA and other critical macromolecules, inhibiting essential cell function and nucleic acid synthesis, thereby compromising the organism's viability.

Dosage and Administration Information

Official Administration Guidelines

Vermox-plus, a fixed-dose combination containing Mebendazole and Quinfamide, is designated for oral administration only. The usage protocol is structured around short-term treatment courses, which can be defined either by a single dose or a multi-day regimen, depending on the specific parasitic infection being managed.

Dosing and Scheduling Principles

For many common infections addressed by the Mebendazole component, the typical treatment is a single, specific dose of the combination product. For other infections, the standard regimen involves administering a dose equivalent to 100 mg of Mebendazole twice daily for three consecutive days. The medicine may be taken with or without food, consistent with established pharmacological profiles for its active components.

Administration Technique

The formulation is frequently provided as a chewable tablet. When using this form, the medicine must be chewed completely before swallowing to ensure proper delivery of the active ingredients. Technical specifications indicate that non-chewable forms can be swallowed whole, or they may be crushed and mixed with a small amount of food or liquid, which is often used to facilitate administration, particularly in the pediatric patient group.

Course Duration and Repeat Treatment

Treatment is intended to be short-term. The protocol advises that a second course of treatment is only indicated if the infection persists or if reinfection is confirmed. This subsequent course is typically administered 2 to 4 weeks after the completion of the initial administration. The same dose schedules are generally applied to adults and children above the minimum age established in the product labeling.

Recent Clinical Evidence

Research evidence / Overview of studies for Vermox-plus

Research Evidence for Mixed Intestinal Parasitic Infections

The combination of Mebendazole and Quinfamide was studied for its potential application in conditions characterized by mixed intestinal parasitic infections (involving both parasitic worms and protozoa). The evidence base consists of randomized controlled trials (RCTs) and controlled studies. These designs used in research exploring how specific outcomes related to the presence of parasites change over defined time intervals, making the evidence part of the broader research base for dual-action antiparasitic agents.

Types of Studies Used to Examine Treatment Outcomes

The evidence is drawn from controlled clinical trials where the combination was evaluated in patients. Researchers monitored specific outcomes, focusing primarily on the parasitosis eradication rate, which is measured by the absence of parasitic forms in stool samples collected post-treatment. Studies reported measurements of these short-term eradication rates, sometimes evaluating the combination alongside other treatments or a placebo. These evaluations provide data related to symptom patterns observed during the study period.

Follow-up Duration and Longer-Term Research

Clinical studies typically focused on short-term symptom changes. Follow-up periods were often limited to around two weeks post-treatment. Consequently, long-term effects are not fully established. There is limited information for long-term outcomes or the durability of the effect after the initial assessment. Extended follow-up data tracking symptom recurrence remain insufficient.

Research in Specific Patient Groups

Research explored the use of this combination, primarily evaluating pediatric populations in regions where mixed parasitic infections are highly endemic, such as parts of Mexico. Results reflect those specific populations. Data for certain groups, such as the general adult population or individuals in non-endemic regions, remain insufficient.

Evidence Gaps and Research Uncertainty

The scientific literature highlights several areas where more research is needed. Comparative evidence is lacking for the fixed-dose combination versus sequential single-agent therapy. Furthermore, the evidence quality varies across studies, and the sample sizes were modest in some key clinical trials. These limitations mean that findings describe group patterns, and research is ongoing to gather more comprehensive data.

Key Studies & References

Efficacy and safety of the combination mebendazole-quinfamide versus mebendazole in children with intestinal parasites

Frequently Asked Questions (FAQ)

Common questions about Vermox-plus (FAQ)

Q: Is Vermox-plus the same as regular Vermox?

A: Official information describes Vermox-plus as a fixed-dose combination containing Mebendazole and an anti-protozoal agent. Regulatory labeling often describes Mebendazole (the component frequently marketed as Vermox) as a single-ingredient product. The combination formulation is intended to provide broader coverage against different types of parasitic infections.

Q: How quickly can I expect to see an effect after taking Vermox-plus?

A: Official information regarding the Mebendazole component's mechanism of action shows that it gradually immobilizes and kills the parasites. Because the dead parasites are eliminated in the feces, the process may require several days after the treatment is completed to be fully noticeable. Information regarding efficacy is typically measured by parasite clearance rates following the course of treatment.

Q: Does Vermox-plus interact with common pain relievers like paracetamol?

A: Official regulatory data for the Mebendazole component suggests that no known interaction was found with Paracetamol (acetaminophen), a common pain reliever. Reviewing all medications and supplements with a healthcare provider is generally recommended before starting any new treatment.

Q: What happens if I miss a dose of Vermox-plus?

A: Regulatory guidance for the Mebendazole component states that if a dose is missed, official guidance suggests it be taken as soon as it is remembered unless it is nearly time for the next scheduled dose. Official guidance advises against doubling doses to compensate for a missed one.

Q: Is Vermox-plus covered by medical guidelines for its intended use?

A: One of the active ingredients, Mebendazole, is included in the World Health Organization’s List of Essential Medicines for its role as an anthelmintic. This inclusion reflects the component's established importance as an anthelmintic in public health contexts. Specific medical guidelines for the combined formulation may vary by region.

Q: Can I take Vermox-plus if I have a history of seizures?

A: Official adverse event reports note that convulsions have been reported as a serious adverse reaction, particularly when given to infants below one year of age. The other component, Tinidazole, is also associated with a rare risk of seizures. The full safety profile, including information on rare risks, is typically reviewed by a healthcare professional.

Q: Is it necessary to finish the entire course of Vermox-plus even if symptoms improve?

A: Official administration instructions for the Mebendazole component advise that the medicine should be taken exactly as prescribed for the full time of treatment. Following the complete course is intended to help ensure the infection is entirely cleared and to reduce the risk of the infection recurring.

Q: Why is Vermox-plus not recommended for people with kidney problems?

A: Regulatory data on the Mebendazole component suggests that no dose adjustment is typically necessary for patients with varying degrees of renal impairment (kidney issues). The official labeling primarily advises caution for patients with hepatic impairment (liver issues) due to potential changes in drug concentration.

Q: Are there any known psychiatric side effects reported with Vermox-plus?

A: The official adverse event profile for the components lists rare effects related to the nervous system. Specifically, rare psychiatric effects reported include reports of confusion and depression. Changes in mood or thinking are important observations that are typically discussed with a healthcare provider.

Q: Does the time of day matter when taking Vermox-plus?

A: For dosing regimens that require two daily administrations, regulatory guidance suggests taking one dose in the morning and one in the evening, ideally separated by 10–12 hours. A single dose can generally be taken at any time of day, but patients are advised to follow the official administration schedule precisely.

Q: What kind of patient monitoring is mentioned in official guidelines for Vermox-plus?

A: Official labeling for the Mebendazole component states that blood counts should be monitored if the medicine is used at higher doses or for a prolonged duration. This monitoring is in place to check for rare serious blood-related side effects.

Q: Does Vermox-plus interact with alcohol?

A: Official documents state that the consumption of alcohol or products containing alcohol (such as certain liquid medicines) is advised to be avoided during treatment and for up to 3 days after completion of therapy. This is due to the potential for an adverse reaction, which can include symptoms like flushing and vomiting.

Q: Does Vermox-plus require a prescription in most places?

A: The regulatory classification for Mebendazole, one of the components, varies by region. It is often listed as prescription-only (℞-only) in several major countries like the US and UK, but its specific availability may differ depending on local regulations and formulation strength.

Q: Can Vermox-plus affect sleep or cause drowsiness?

A: Adverse event reports for the components include effects on the nervous system, such as reports of drowsiness (feeling sleepy) and insomnia (trouble sleeping). Persistent or concerning changes in sleep patterns or alertness are observations that may be relevant to a healthcare provider.

Q: Are there any common foods or supplements that should be avoided when using Vermox-plus?

A: Official labeling notes that administering the medicine with a high-fat meal is a documented pharmacokinetic interaction that increases the systemic absorption of the Mebendazole component. This change in systemic exposure may be a relevant factor in the drug’s overall profile.

Q: Can older adults use Vermox-plus?

A: The medicine is generally established for use by adults, including older adults. However, official guidance notes that older patients are more likely to have age-related liver or kidney issues which could potentially affect how the medicine is processed in the body and may necessitate specific monitoring.

Q: Do regulatory bodies classify Vermox-plus as a safe medicine?

A: Official documents define the safety profile by listing absolute contraindications (conditions where the drug should not be used, such as during pregnancy or in children below age 1) and providing warnings about the risk of rare but serious adverse reactions. The medicine is intended for use under specific conditions and parameters as defined in official labeling.

Q: Does taking Vermox-plus require any special dietary changes?

A: Official instructions for the Mebendazole component state that no special preparations or diets (such as fasting or using laxatives) are necessary before, during, or immediately after treatment. However, the high-fat meal interaction should be considered during administration.

Q: What are the signs of a serious allergic reaction to Vermox-plus?

A: Official adverse reaction reports describe severe hypersensitivity reactions that can occur. Signs can include large, hive-like swelling on the face, eyelids, lips, or throat, or the development of rash, blisters, or peeling skin. These are considered severe effects that typically require immediate attention from a healthcare provider.

Q: Does age affect how Vermox-plus works in the body?

A: While the medicine is established for those 2 years and older, official guidance notes that older adults are more likely to have age-related organ issues (specifically liver and kidney problems). These issues could potentially affect how the body processes the medicine, which may require caution or monitoring.

How should Vermox-plus be stored and disposed of?

How to Store and Dispose of Vermox-plus?

This medicine must be stored according to regulatory requirements to ensure the stability of the active ingredients, Mebendazole and Quinfamide.

Storage Conditions

Vermox-plus must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture and should not be frozen.

The medication must remain in its tightly closed container and must be kept out of the reach of children. Use of the medicine is restricted to the expiration date printed on the packaging.

Disposal Instructions

Unused or expired Vermox-plus must be disposed of according to local regulations. Users are instructed to consult a healthcare professional regarding disposal protocols. The medicine should not be thrown into wastewater or common household trash, as specified by official guidance.

Vermox-plus